J.P. Morgan is out with its report today on Vertex Pharmaceuticals VRTX, maintaining Neutral.
In a note to clients, J.P. Morgan writes, "We remain very impressed by VX-770 in the G551D CF population and together with Class 4/5 CF patients, we estimate a peak opportunity approaching $1B for this franchise. That said, we are not optimistic with the potential for robust combo (VX-770+VX-809) data targeting the larger F508del CF population. Hence, with a bullish outlook for VX-770 and for telaprevir in HCV already assumed in Street models, we are maintaining our
Neutral rating on VRTX shares."
J.P. Morgan has a $46 PT on VRTX.
Shares of VRTX closed Friday at $55.05, down 0.88% from Thursday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in